Promega Signs a Worldwide Agreement with Merck to Develop MSI Technology as CDx for Keytruda

Promega Signs a Worldwide Agreement with Merck to Develop MSI Technology as CDx for Keytruda

Shots:

  • Promega and Merck collaborated to develop Promega’s microsatellite instability (MSI) technology as an on-label solid tumor CDx for use with Merck’s Keytruda (pembrolizumab)
  •  Promega’s Microsatellite Instability technology measures the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) occurring in a solid-tumors, used to characterize tumors and guide therapeutic choices for MSI-High cancer types
  • The global companies will initially pursue approval for Promega MSI CDx in the US & China. Additionally, Promega intend to get approval for its MSI in IVD test with its anticipated launch in H1’20 in the US, China & EU

Click here to­ read full press release/ article | Ref: Business wire | Image: Reuters